We consider any residual impairment(s), such as complications arising from:
a. Graft-versus-host (GVH) disease.
b. Immunosuppressant therapy, such as frequent infections.
c. Significant deterioration of other organ systems.
113.01 Category of Impairments, Malignant Neoplastic Diseases
113.03 Malignant solid tumors. Consider under a disability:
A. For 2 years from the date of initial diagnosis. Thereafter, evaluate any residual
impairment(s) under the criteria for the affected body system.
OR
B. For 2 years from the date of recurrence of active disease. Thereafter, evaluate
any residual impairment(s) under the criteria for the affected body system.
113.05 Lymphoma (excluding T-cell lymphoblastic lymphoma—113.06. (See 113.00K1.)
A. Non-Hodgkins lymphoma, including Burkitt's and anaplastic large cell. Persistent
or recurrent following initial antineoplastic therapy.
OR
B. Hodgkin’s disease with failure to achieve clinically complete remission, or recurrent
disease within 12 months of completing initial antineoplastic therapy.
OR
C. With bone marrow or stem cell transplantation. Consider under a disability until
at least 12 months from the date of transplantation. Thereafter, evaluate any residual
impairment(s) under the criteria of the affected body system.
113.06 Leukemia. (See 113.00K2.)
A. Acute leukemia (including T-cell lymphoblastic lymphoma and juvenile chronic myelogenous
leukemia (JCML)). Consider under a disability until at least 24 months from the date
of diagnosis or relapse, or at least 12 months from the date of bone marrow or stem
cell transplantation, whichever is later. Thereafter, evaluate any residual impairment(s)
under the criteria for the affected body system.
OR
B. Chronic myelogenous leukemia (except JCML), as described in 1 or 2:
1. Accelerated or blast phase. Consider under a disability until at least 24 months
from the date of diagnosis or relapse, or at least 12 months from the date of bone
marrow or stem cell transplantation, whichever is later. Thereafter, evaluate any
residual impairment(s) under the criteria for the affected body system.
2. Chronic phase, as described in a or b:
a. Consider under a disability until at least 12 months from the date of bone marrow
or stem cell transplantation. Thereafter, evaluate any residual impairment(s) under
the criteria for the affected body system.
b. Progressive disease following initial antineoplastic therapy.
113.09 Thyroid gland.
A. Anaplastic (undifferentiated) carcinoma.
OR
B. Carcinoma with metastases beyond the regional lymph nodes progressive despite radioactive
iodine therapy.
113.12 Retinoblastoma.
A. With extension beyond the orbit.
OR
B. Persistent or recurrent following initial antineoplastic therapy.
OR
C. With regional or distant metastases.
113.13 Brain tumors. (See 113.00K4.) Highly malignant tumors, such as Grades III and IV astrocytomas,
glioblastoma multiforme, ependymoblastoma, medulloblastoma or other primitive neuroectodermal
tumors (PNETs) with documented metastases, diffuse intrinsic brain stem gliomas, or
primary sarcomas.
113.21 Neuroblastoma.
A. With extension across the midline.
OR
B. With distant metastases.
OR
C. Recurrent.
OR
D. With onset at age 1 year or older.